Jump to content

Serdar Bulun

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Theroadislong (talk | contribs) at 21:06, 8 January 2016 (remove copyrighted photograph). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

  • Comment: Do not make statements such as "Bulun has been a widely recognized pioneer of molecular medicine in the field of gynecology" in the voice of Wikipedia. Such statements must be attributed. Robert McClenon (talk) 00:13, 8 January 2016 (UTC)
Serdar Bulun
Born
Malatya, Turkey
Scientific career
Fields
Institutions

Websitehttp://www.feinberg.northwestern.edu/sites/obgyn/research/labs/bulun/index.html

Introduction

Serdar Bulun, MD is a physician scientist, who has made significant contributions to the understanding and treatment of the common gynecologic diseases, endometriosis and uterine fibroids.[1][2][3][4][5]

He currently serves as the obstetrician and gynecologist-in-chief of the Prentice Women’s Hospital of Northwestern Memorial Hospital in Chicago, IL and Chair of Northwestern University’s Department of Obstetrics and Gynecology, which is one of the largest and most influential women’s health programs in the world. He is one of the rare Turkish-trained physicians, who rose to the rank of a clinical department chair in the United States.

Bulun was born in Malatya, Turkey in 1959 and moved to Istanbul to attend Robert College and thereafter Istanbul University School of Medicine (Çapa Tıp Fakültesi). He received his residency training in obstetrics and gynecology at the University at Buffalo in New York and pursued a sub-specialty fellowship in reproductive endocrinology-infertility at the University of Texas Southwestern Medical Center at Dallas. Starting from 2003, he has set up a comprehensive women’s health research program at Northwestern, and recruited and supported numerous faculty who focus on steroid hormone-related pathology of uterine, breast and ovarian disorders. Throughout his career, Dr. Bulun has been awarded over $70 million of research funding in endometriosis, uterine fibroids and breast cancer. In his laboratory, he mentored many PhD and MD-PhD students and postdoctoral research fellows.[1][2][6]

Bulun has made a significant global impact on medicine via contributions to the genetics and steroid biology of the common gynecologic disorders, endometriosis and uterine fibroids, which collectively affect more than 200 million women around the world.[1][2][6] He discovered the epigenetic basis of endometriosis and introduced aromatase inhibitors as a novel class of drugs to effectively treat it.[3] His team isolated tumor stem cells from uterine fibroids and targeted these to treat this disease.[4] He also contributed significantly to the genetics and systems biology aspects of hormone-responsive disorders of the breast including cancer.[7][8][9] He has published more than 200 scientific articles including reports in top-ranked journals such as the New England Journal of Medicine, Nature Medicine, and the Proceedings of the National Academy of Sciences of the USA; 65 of these articles have been cited more than 100 times - his h-index is currently 71.

Bulun is the editor-in-chief of Seminars in Reproductive Medicine. He has been elected to the National Academy of Medicine (formerly known as the Institute of Medicine), the Association of American Physicians and the American Society for Clinical Investigation, the honor societies for physician-scientists. He served as the 2015 president for the Society for Reproductive Investigation. He has received several prestigious awards, including the National Institutes of Health-MERIT award for his groundbreaking research work in endometriosis and the American Society of Reproductive Medicine Distinguished Researcher Award.

Key Scientific Contributions to Medicine

  • Introduced aromatase inhibitors as a novel treatment for endometriosis[3]
  • Discovered the key epigenetic defects in endometriosis leading to progesterone resistance[1]
  • Isolated and therapeutically targeted stem cells in uterine fibroids[2]
  • Discovered the first set of gain-of-function mutations affecting the aromatase gene leading to breast development and estrogen excess in prepubertal boys and girls[7][8]

Key Honors

References

Category:Articles created via the Article Wizard

Status

  1. ^ a b c d Bulun SE. Endometriosis.N Engl J Med.2009;360:268-79.
  2. ^ a b c d Bulun SE. Uterine fibroids.N Engl J Med.2013;369:1344-55.
  3. ^ a b c Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis?Fertil Steril.2006;85:1307-18.
  4. ^ a b Ono M, Yin P, Navarro A, et al. Paracrine activation of WNT/beta-catenin pathway in uterine leiomyoma stem cells promotes tumor growth.Proc Natl Acad Sci USA.2013;110:17053-8.
  5. ^ Dyson MT, Roqueiro D, Monsivais D, et al. Genome-wide DNA methylation analysis predicts an epigenetic switch for GATA factor expression in endometriosis.PLoS Genet.2014;10(3):e1004158.
  6. ^ a b Bulun SE, Lin Z, Imir G, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.Pharmacol Rev.2005;57:359-83.
  7. ^ a b Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene.N Engl J Med.2003;348:1855-65.
  8. ^ a b Demura M, Martin RM, Shozu M, et al. Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene.Hum Mol Genet.2007;16:2529-41.
  9. ^ Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta.Cancer Res.2001;61:2328-34.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Serdar_Bulun&oldid=698884986"